Table 1.

Characteristics of study participants

n (male/female)	58 (43/15)
Age (years)	55 ± 12
Height (m)	1.66 ± 0.08
Weight (kg)	86.2 ± 28.2
BMI (kg/m2)	31.1 ± 9.1
Duration of diabetes (years)	11 ± 7
FPG (mg/dL)	154 ± 46
HbA1c (%)	7.2 ± 1.2
HbA1c (mmol/mol)	56 ± 13
eGFR (mL/min/1.73 m2)	76.4 ± 21.0
Hypertension (%)	74.1
Dyslipidemia (%)	72.4
CVD (%)	19.0
Concomitant antidiabetic medication
None (%)	19.0
SU (%)	50.0
Metformin (%)	65.5
TZD (%)	17.2
AGI (%)	6.9
SGLT2 inhibitor (%)	5.2

AGI, α‐glucosidase inhibitor; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; SGLT2, sodium–glucose cotransporter 2; SU, sulfonylurea; TZD, thiazolidinedione.